Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 49.605 mg (equivalent: pioglitazone, qty 45 mg) - tablet, uncoated - excipient ingredients: carmellose calcium; hyprolose; lactose monohydrate; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 33.07 mg (equivalent: pioglitazone, qty 30 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; carmellose calcium; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - celecoxib, quantity: 200 mg - capsule, hard - excipient ingredients: carrageenan; titanium dioxide; sodium lauryl sulfate; gelatin; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; iron oxide red; microcrystalline cellulose; iron oxide yellow; purified talc - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - celecoxib, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; carrageenan; gelatin; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; indigo carmine; titanium dioxide; purified talc; colloidal anhydrous silica - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 550 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; sunset yellow fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and noumed cephalexin is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to noumed cephalexin. renal function studies should be perfomed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; povidone; stearic acid - for the temporary relief of pain associated with headache, migraine headache, tension headache, neuralgia, osteoarthritis, arthritis, rheumatic pain, fibrositis, back pain, muscular aches and pains, tennis elbow, colds and flu, sore throat, sinus pain, toothache and dental procedures, and menstruation/period pain. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 10 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; iron oxide yellow; iron oxide red; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; calcium hydrogen phosphate; colloidal anhydrous silica; pregelatinised maize starch; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide yellow; sodium stearylfumarate; hypromellose phthalate; calcium hydroxide; hypromellose; purified talc; titanium dioxide; dibutyl sebacate; hyprolose; mannitol - noumed rabeprazole is indicated for treatment and prevention of relapse of gastro-oesophageal reflux disease; symptomatic treatment of gastro-oesophageal reflux disease; treatment of duodenal ulcers; treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,noumed sandoz is also indicated, in combination with clarithromycin and amoxycillin, for eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis; and healing of peptic ulcers in patients with helicobacter pylori associated ulcers.